Polypill not linked to reduced cognitive decline in seniors
Jan 30, 2023
But a polypill with or without aspirin is associated with reduced functional decline for those aged 65 years or older with cardiovascular risk factors.
Insurance company argues against defending senior living operator in wrongful death suit
By
Kimberly Bonvissuto
Jan 18, 2023
A policy lapse means that an insurer does not have to defend an assisted living community from a wrongful death lawsuit, the insurer is arguing in federal court.
FDA approves second drug for Alzheimer’s disease, despite safety concerns
Jan 06, 2023
The approval of lecanemab-irmb (Leqembi) comes after controversial approval in 2021 of aducanumab (Aduhelm), which met with criticism over concerns about that drug’s effectiveness, safety and pricing.
5α-reductase inhibitors linked to depression, but not dementia
Dec 29, 2022
The magnitude of association for finasteride and dutasteride with dementia decreased over time and became nonsignificant.
Study explores impact of FDA approval of aducanumab on trial participation
Dec 06, 2022
Individuals who were independently aware of the FDA decision demonstrated a reduced willingness to participate.
Review links hearing aid devices with reduced cognitive decline
Dec 06, 2022
Further, the use of devices is linked to a 3% improvement in cognitive test scores in the short term.
More news for Tuesday, Dec. 6
By
Kimberly Bonvissuto
Dec 06, 2022
LeadingAge Minnesota Foundation invests $400,000 in 24 workforce grants … Merger targets strengthening assisted living … FCC opens applications for $5M internet pilot program for affordable senior...
Subjective cognitive decline tied to incident dementia in Black, Latinx individuals
Dec 01, 2022
Subjective cognitive decline was associated with increased rates of incident dementia over time in the multiracial population, Latinx and non-Latinx Black individuals.
Lecanemab reduced markers of amyloid in early Alzheimer’s disease
Dec 01, 2022
Moderately less decline was seen in cognition and function at 18 months with lecanemab versus placebo.
Second death in trial of experimental Alzheimer’s drug raising concerns
Nov 29, 2022
Doctors suspect that by stripping away amyloid deposits, lecanemab weakens blood vessels and leaves them vulnerable to bleeds.